Horizon BCBS coverage for Zepbound (Osa)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

BMI of 30 or higher
Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

OSA with obesity (Zepbound)

All of:

Diagnosis of obstructive sleep apnea (OSA) (medical records required)
Polysomnography (PSG) or home sleep apnea test performed (sleep study required)
AHI >= 15 events/hour from baseline (prior to initiation of pharmacotherapy) (sleep study required)
Requested agent is Zepbound
BMI >= 30 kg/m2 (medical records required)
Will NOT use in combination with another weight loss agent
Will NOT use in combination with another GLP-1 receptor agonist
No FDA labeled contraindications to requested agent
Currently on low-calorie diet, increased physical activity, and behavioral modifications

Documentation to bring

Medical records confirming diagnosis of obstructive sleep apnea (OSA)
Sleep study results (polysomnography or home sleep apnea test) showing AHI >= 15 events/hour at baseline
Medical records confirming BMI >= 30 kg/m2

Quantity limits

2.5mg — 4 vials or 4 pens per 180 days (84-day)
5mg, 7.5mg, 10mg, 12.5mg, 15mg — 4 vials or 4 pens per 28 days

Approval and renewal

Initial approval: 6 months
Renewal: every 6 months
To renew, the plan looks for Patient must have had clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). OSA diagnosis and AHI/BMI requirements are NOT re-verified at renewal — only clinical benefit confirmation is required.

Not covered when

Concomitant use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Concomitant use with another GLP-1 receptor agonist
Any FDA labeled contraindications to the requested agent

Policy note: PAP therapy trial is NOT required prior to approval — the policy does not mandate a prior PAP/CPAP trial. Both patients currently on PAP and those not on PAP are eligible (consistent with SURMOUNT-OSA trial design referenced in the document). AHI >= 15 events/hour corresponds to moderate-to-severe OSA. Initial approval is 6 months (non-obesity indication). Renewal is 6 months with clinical benefit required (reduction in AHI or decrease in Epworth Sleepiness Scale).

verified June 5, 2026 · source: glp1-for-non-diabetic-use.pdf